Table: Santen Pharm -9-MTH group results (IFRS)

SANTEN PHARMACEUTICAL

04/02/2021 06:00

Feb 4 (Reuters)- 
              Santen Pharmaceutical Co Ltd 
              CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified) 
                   9 months ended      9 months ended       Year to 
                  Dec 31, 2020        Dec 31, 2019     Mar 31, 2021 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              181.79              182.33           235.00    
                   (-0.3 pct)          (+5.3 pct)       (-2.7 pct)  
  Operating           27.27               28.94            35.00    
                   (-5.8 pct)          (-14.0 pct)      (+4.4 pct)  
  Pretax              26.96               28.96            34.00    
                   (-6.9 pct)          (-10.6 pct)      (+5.9 pct)  
  Net                 21.12               20.30                     
                   (+4.0 pct)          (-13.2 pct)                  
  EPS Basic         52.86 yen           50.86 yen        58.35 yen  
  EPS Diluted       52.74 yen           50.71 yen                   
  Ann Div                               27.00 yen        28.00 yen  
  -Q2 Div           14.00 yen           13.00 yen                   
  -Q4 Div                               14.00 yen        14.00 yen  
 
  NOTE - Santen Pharmaceutical Co Ltd. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4536.T